October 7, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced it has strengthened the U.S. government’s access to safety injection devices through increased manufacturing capacity and domestic supply.
The new manufacturing lines for syringes and needles, which were completed on an accelerated timeline, represent the public-private partnership between BD and HHS’ Assistant Secretary for Preparedness and Response (ASPR).
The new lines increase capacity of BD’s existing needle and syringe supply capabilities domestically. To date, the company has provided several hundred million injection devices to the federal campaign.
In July 2020, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) invested approximately $42 million into a $70 million capital project to further expand BD’s operations and manufacturing lines in Holdrege, Nebraska.
In addition to ramping up the manufacturing of needles and syringes domestically to meet U.S. needs for the COVID-19 pandemic, BD is working to help ensure the global community is prepared for future pandemic vaccination. BD previously announced plans to invest $1.2 billion over four years to enhance its manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems – allowing for continued growth of new injectable drugs and vaccines.